蛋白酪氨酸磷酸酶非受体型23在肝细胞癌组织中的表达及其与TACE治疗疗效的关系  

Expression of Protein Tyrosine Phosphatase Non-receptor Type 23 in Hepatocellular Carcinoma Tissues and its Relationship with the Efficacy of Transcatheter Arterial Chemoembolization

作　　者：李宝平 徐军 LI Bao-ping;XU Jun(Department of Oncology,Xianyang Central Hospital,Xianyang Shaanxi 712000)

机构地区：[1]咸阳市中心医院肿瘤科,陕西咸阳712000 [2]陕西省核工业二一五医院肿瘤外科,陕西咸阳712000

出　　处：《医学临床研究》2022年第8期1178-1181,共4页Journal of Clinical Research

摘　　要：【目的】探讨蛋白酪氨酸磷酸酶非受体型23(PTPN23)在肝细胞癌(HCC)组织中的表达及其与经肝动脉化疗栓塞术(TACE)治疗疗效的关系。【方法】选择在两院接受救治的102例HCC患者作为研究对象,用蛋白质免疫印迹法检测HCC组织中PTPN23蛋白表达水平,用实体瘤疗效评价标准的修订标准(mRECIST)评价TACE治疗疗效。分析HCC组织中PTPN23水平与TACE治疗疗效的关系。【结果】102例HCC患者经TACE治疗后18例(17.65%)完全缓解,33例(32.35%)部分缓解,21例(20.59%)疾病稳定,30例(29.41%)疾病进展。治疗无效组(30例)患者PTPN23蛋白水平为0.80±0.18,明显低于治疗有效组(72例)的1.07±0.23,且差异有统计学意义(P<0.05)。PTPN23评价TACE治疗疗效的ROC曲线下面积、敏感度和特异度分别为0.819、70.00%和79.17%。多因素Logistic回归分析结果显示,肿瘤直径≥5cm、PTPN23<0.90是TACE治疗疗效的独立危险因素(P<0.05)。【结论】检测HCC组织中PTPN23表达水平有助于判断TACE治疗疗效,HCC组织中PTPN23表达水平低是影响TACE治疗疗效的独立危险因素。【Objective】To investigate the expression of protein tyrosine phosphatase non-receptor type 23(PTPN23)in hepatocellular carcinoma(HCC)tissues and its relationship with the efficacy of transcatheter arterial chemoembolization(TACE).【Methods】A total of 102 patients with HCC who were treated in the two hospitals were selected as the research subjects.Western blot was used to detect the expression of PTPN23 protein in HCC tissues;the modified response evaluation criteria in solid tumor(mRECIST)was used to evaluate the efficacy of TACE treatment.The relationship between the PTPN23 level in HCC tissues and the therapeutic effect of TACE was analyzed.【Results】After TACE treatment in 102 HCC patients,18 patients(17.65%)CR,33(32.35%)PR,21(20.59%)SD and 30(29.41%)PD.The PTPN23 protein level in the treatment ineffective group(n=30)was 0.80±0.18,which was lower than that in the treatment effective group 1.07±0.23,and the difference was statistically significant(P<0.05).The area under the ROC curve,sensitivity and specificity of PTPN23 to evaluate the efficacy of TACE treatment were 0.819,70.00%and 79.17%,respectively.Multivariate Logistic regression analysis showed that tumor diameter≥5 cm and PTPN23<0.90 were independent risk factors for TACE treatment(P<0.05).【Conclusion】The detection of PTPN23 expression in HCC tissues is helpful to judge the efficacy of TACE treatment.Low expression of PTPN23 in HCC tissues is an independent risk factor for the efficacy of TACE therapy.

关 键 词：癌 肝细胞/病理学 蛋白质酪氨酸磷酸酶 非受体23型 化学栓塞 治疗性 肝动脉 

分 类 号：R735.7[医药卫生—肿瘤]